# Risk: __Lack of vaccines and agent-specific drugs__ (PBN__Risk_1540)

## Property: has_RiskISO_Impact

* [Biodiversity and ecosystem services](../RiskISO/PBN__RiskISO_Purpose_4)

## Property: has_RiskTechnology

* [vaccine development](../Technology/PBN__Technology_837)
* [antiviral drug research](../Technology/PBN__Technology_838)

## Property: has_RiskSubject

* [general population](../Stakeholder/PBN__Stakeholder_9)
* [healthcare workers](../Stakeholder/PBN__Stakeholder_68)

## Property: has_RiskType

* [technological](../RiskType/PBN__RiskType_5)

## Property: has_RiskISO_Purpose

* [Attractiveness](../RiskISO/PBN__RiskISO_Impact_9)

## Property: has_RiskOwner

* [pharmaceutical companies](../Stakeholder/PBN__Stakeholder_124)
* [government research institutions](../Stakeholder/PBN__Stakeholder_994)

## Property: has_RiskMitigation

* [Investment in research and development for vaccines and agent-specific drugs.](../RiskMitigation/PBN__RiskMitigation_2069)

## Property: has_RiskName

Limited prevention and treatment options during viral epidemics.

## Property: has_RiskDescription

Inadequacy of vaccines and agent-specific drugs for respiratory viruses.

## Property: has_RiskSource

* [jefferson_physical_2008](../Article/PBN__Article_22)

## Property: has_RiskGBN

* [No](../RiskGBN/PBN__RiskGBN_0)

## Property: has_RiskHealth

* [physical](../RiskHealth/PBN__RiskHealth_0)

